Table 1 Patient characteristics of 401 advanced stage cHL patients treated within clinical trials HD12 and HD15 and prediction analysis of the adjusted gene predictor.

A. Patient characteristics with risk groups resulting from the adjusted gene predictor
	All		High risk		Low risk
	N = 401		N = 149		N = 252
	N	%	N	%	N	%
Age (years)
Median	33		39		29
Range	18–60		18–60		18–59
18–45	317	79.1	103	69.1	214	84.9
45–60	84	20.9	46	30.9	38	15.1
Sex
Female	153	38.2	38	25.5	115	45.6
Male	248	61.8	111	74.5	137	54.4
cHL Subtype
Mixed cellularity	116	28.9	65	43.6	51	20.2
Nodular sclerosis	257	64.1	74	49.7	183	72.6
Lymphocyte-rich	11	2.7	3	2	8	3.2
Lymphocyte-depleted	4	1	3	2	1	0.4
cHL NOS	13	3.2	4	2.7	9	3.6
IPS (grouped)
0–1	114	28.4	29	19.5	85	33.7
2–3	224	55.9	92	61.7	132	52.4
4–7	63	15.7	28	18.8	35	13.9
Relapse/Death
None	232	57.9	81	54.4	151	59.9
Progression/Relapse only	79	19.7	30	20.1	49	19.4
Death only	54	13.5	29	19.5	25	9.9
Both	36	9	9	6	27	10.7

C. Progression-free survival (PFS)
Variable	univar. P	multivar. P
Age	0.0002	0.0006
Sex (male)	0.0014	0.0034
adj. gene predictor	0.1452	0.7881

E. Adj. gene predictor and IPS risk factors
Variable	stand. estimate β	significance P
Intercept	−0.98	<0.0001
Sex (male)	0.55	<0.0001
Age ≥ 45 yrs	0.46	<0.0001
Leukocytes ≥ 15,000/	0.66	<0.0001
Hb < 10.5 g/dL	0.52	<0.0001
Lymphocytes < 8% of WBC	0.39	0.0223
Albumin < 4 g/dL	−0.07	0.4928
Stage IV	−0.11	0.2328

Multiple linear regression of adjusted gene predictor on IPS factors, R² = 0.22.
(A) Characteristics of high-risk and low-risk patients analyzed in this study. (B) Cox regression of progression-free survival (PFS) on sex, age and the adjusted gene predictor. (C) Cox regression of overall survival (OS) on sex, age and the adjusted gene predictor. (D) Cox regressions of PFS and OS on the IPS and the adjusted gene predictor. (E) Multiple linear regression of the adjusted gene predictor on the seven risk factors of the IPS.

Search